Israeli firm Aposense has raised more than $24 million from its initial public offering. The company is engaged in the development of diagnostic agents and drugs that work by targeting programmed cell death, a factor in various conditions, in vivo. The company is currently undertaking Phase II clinical studies of a PET tracer used in imaging cell death.

Related Summaries